Immunocore Holdings plc ADR Dossier
Qualitative Analysis
Business overview
Immunocore Holdings plc (Nasdaq: IMCR) is a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies called ImmTAX (Immune mobilizing monoclonal TCRs Against X disease). The company's proprietary platform is designed to redirect the immune system to recognize and kill diseased cells, including cancer, infectious, and autoimmune targets. Immunocore's lead commercial product, KIMMTRAK (tebentafusp-tebn), is the first-ever approved TCR therapeutic and is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). The company is leveraging its validated platform to advance a deep pipeline of clinical and preclinical candidates across multiple therapeutic areas.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the global commercial footprint of KIMMTRAK (tebentafusp) for HLA-A*02:01-positive metastatic uveal melanoma (mUM) by securing regulatory approvals and launching in new international geographies, deepening penetration in US community centers, and completing pricing negotiations in Europe.
Expected impact: Drives near-term revenue growth and establishes KIMMTRAK as the global standard of care in mUM, building on its $400 million net sales achieved in 2025.
Pioneering the application of the soluble T-cell receptor (TCR) ImmTAX platform beyond oncology and infectious diseases into autoimmune disorders, starting with candidates targeting type 1 diabetes (IMC-S118AI) and atopic dermatitis (IMC-U120AI).
Expected impact: Broadens the therapeutic reach and long-term commercial potential of the proprietary TCR platform into multi-billion dollar autoimmune markets.
Advancing the PRAME-targeting bispecific pipeline, led by brenetafusp (IMC-F106C) in the registrational Phase 3 PRISM-MEL-301 trial for first-line advanced cutaneous melanoma, alongside next-generation candidates like IMC-P115C.
Expected impact: Establishes a highly valuable second oncology franchise targeting PRAME, which is widely expressed in multiple solid tumors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Er-Kim acts as the exclusive partner to distribute and commercialize KIMMTRAK (tebentafusp) in Turkey, the Middle East, North Africa (MENA), the Caucasus, and the Commonwealth of Independent States (CIS) regions.
Terms: Specific financial terms were not disclosed; Er-Kim leverages its local commercial infrastructure to accelerate patient access in high-unmet-need territories.
Collaborating to evaluate Immunocore's PRAME-targeting candidate, brenetafusp, in combination with Bristol Myers Squibb's anti-PD-1 therapy, Opdivo (nivolumab), in the registrational Phase 3 PRISM-MEL-301 study for first-line advanced cutaneous melanoma.
Terms: Clinical collaboration terms where each party provides its respective compound for the trial.